Safety and activity of docetaxel and trastuzumab in HER2 overexpressing metastatic breast cancer a pilot phase ii study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 26, Issue 1, 2003, Pages 95-97

  Montemurro, Filippo ^a   Choa, Gabriella ^a   Faggiuolo, Roberto ^a   Sperti, Elisa ^a   Capaldi, Antonio ^a   Donadio, Michela ^b   Minischetti, Monica ^c   Salomone, Attilio ^c   Vietti Ramus, Guido ^d   Alabiso, Oscar ^e   Aglietta, Massimo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c Ospedale Cottolengo   (Italy)

^d S GIOVANNI BOSCO HOSPITAL   (Italy)

^e MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

Author keywords

Docetaxel; Metastatic breast cancer; Trastuzumab

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOCETAXEL; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; NEUTROPENIA; ONCOGENE NEU; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PROTEIN EXPRESSION; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0037322376     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.COC.0000017087.19671.05     Document Type: Article

References (8)

1. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139.
2. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-2251.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
4. Pegram MD. Docetaxel and Herceptin: foundation for new strategies. Oncologist 2001;6(suppl 3):22-25.
5. Miller AB, Hoogstraten B. Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
6. Burris HA III. Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 2001;28(suppl 3):38-44.
7. Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714-2721.
8. Vogel CL, Cobleigh M, Tripathy D, et al. Superior outcomes with Herceptin (trastuzumab) (H) in fluorescence in situ hybridization (FISH)-selected patients [Abstract 86]. Proc Am Soc Clin Oncol 2001;20:22a.